

# L Lee Dupuis Rph

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6079997/publications.pdf>

Version: 2024-02-01

160  
papers

5,557  
citations

87888

38  
h-index

98798

67  
g-index

163  
all docs

163  
docs citations

163  
times ranked

5350  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 3240-3261.	1.6	454
2	Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update. <i>Journal of Clinical Oncology</i> , 2017, 35, 2082-2094.	1.6	337
3	Guideline for the Management of Fever and Neutropenia in Children With Cancer and/or Undergoing Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2012, 30, 4427-4438.	1.6	311
4	Development and Testing of a Multidimensional iPhone Pain Assessment Application for Adolescents with Cancer. <i>Journal of Medical Internet Research</i> , 2013, 15, e51.	4.3	243
5	Antiemetics: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 2782-2797.	1.6	201
6	Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2006, 24, 5207-5215.	1.6	119
7	Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv357.	6.3	117
8	Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1073-1082.	1.5	112
9	Physical activity reduces fatigue in patients with cancer and hematopoietic stem cell transplant recipients: A systematic review and meta-analysis of randomized trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 122, 52-59.	4.4	111
10	Development and Validation of the Pediatric Nausea Assessment Tool for Use in Children Receiving Antineoplastic Agents. <i>Pharmacotherapy</i> , 2006, 26, 1221-1231.	2.6	96
11	Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation. <i>BMJ Supportive and Palliative Care</i> , 2017, 7, 7-16.	1.6	90
12	Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26542.	1.5	88
13	Construct validity and reliability of a real-time multidimensional smartphone app to assess pain in children and adolescents with cancer. <i>Pain</i> , 2015, 156, 2607-2615.	4.2	85
14	Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2020, 71, 226-236.	5.8	84
15	Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. <i>Pediatric Blood and Cancer</i> , 2014, 61, 393-400.	1.5	79
16	Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatric Blood and Cancer</i> , 2011, 57, 191-198.	1.5	78
17	Symptom assessment in children receiving cancer therapy: the parents' perspective. <i>Supportive Care in Cancer</i> , 2010, 18, 281-299.	2.2	75
18	Anxiety, pain, and nausea during the treatment of standard-risk childhood acute lymphoblastic leukemia: A prospective, longitudinal study from the Children's Oncology Group. <i>Cancer</i> , 2016, 122, 1116-1125.	4.1	72

#	ARTICLE	IF	CITATIONS
19	Validation of the Symptom Screening in Pediatrics Tool in Children Receiving Cancer Treatments. <i>Journal of the National Cancer Institute</i> , 2018, 110, 661-668.	6.3	68
20	2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children. <i>Supportive Care in Cancer</i> , 2017, 25, 323-331.	2.2	67
21	Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 141-150.	5.6	65
22	Defibrotide for the treatment of hepatic veno-occlusive disease in children. <i>Pediatric Blood and Cancer</i> , 2007, 48, 700-704.	1.5	64
23	Clinical Practice Guideline for Systemic Antifungal Prophylaxis in Pediatric Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients. <i>Journal of Clinical Oncology</i> , 2020, 38, 3205-3216.	1.6	63
24	Aprepitant and fosaprepitant drug interactions: a systematic review. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2148-2162.	2.4	62
25	Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1144-1151.	1.5	60
26	A systematic review of symptom assessment scales in children with cancer. <i>BMC Cancer</i> , 2012, 12, 430.	2.6	59
27	Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1506-1512.	1.5	57
28	Pharmacokinetic Disposition and Clinical Outcomes in Infants and Children Receiving Intravenous Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 307-314.	2.0	56
29	Predictors of Viridans Streptococcal Shock Syndrome in Bacteremic Children With Cancer and Stem-Cell Transplant Recipients. <i>Journal of Clinical Oncology</i> , 2004, 22, 1222-1227.	1.6	55
30	Risk Factors for Infection-Related Outcomes During Induction Therapy for Childhood Acute Lymphoblastic Leukemia. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 1064-1068.	2.0	53
31	Initial development of the Symptom Screening in Pediatrics Tool (SSPedi). <i>Supportive Care in Cancer</i> , 2014, 22, 71-75.	2.2	52
32	Efficacy of antibiotic prophylaxis in patients with cancer and hematopoietic stem cell transplantation recipients: A systematic review of randomized trials. <i>Cancer Medicine</i> , 2019, 8, 4536-4546.	2.8	52
33	Outpatient and oral antibiotic management of low-risk febrile neutropenia are effective in children—a systematic review of prospective trials. <i>Supportive Care in Cancer</i> , 2012, 20, 1135-1145.	2.2	46
34	Strategies for Empiric Management of Pediatric Fever and Neutropenia in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2016, 34, 2054-2060.	1.6	45
35	The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2016, 39, 675-687.	3.2	45
36	Management of fatigue in children and adolescents with cancer and in paediatric recipients of haemopoietic stem-cell transplants: a clinical practice guideline. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 371-378.	5.6	44

#	ARTICLE	IF	CITATIONS
37	Evaluation of the electronic self-report Symptom Screening in Pediatrics Tool (SSPedi). <i>BMJ Supportive and Palliative Care</i> , 2018, 8, 110-116.	1.6	41
38	Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27646.	1.5	41
39	Performance of Busulfan Dosing Guidelines for Pediatric Hematopoietic Stem Cell Transplant Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1471-1478.	2.0	39
40	Mind and body practices for fatigue reduction in patients with cancer and hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 210-216.	4.4	39
41	GSTA1 diplotypes affect busulfan clearance and toxicity in children undergoing allogeneic hematopoietic stem cell transplantation: a multicenter study. <i>Oncotarget</i> , 2017, 8, 90852-90867.	1.8	39
42	Utility of peripheral blood cultures in bacteremic pediatric cancer patients with a central line. <i>Supportive Care in Cancer</i> , 2010, 18, 913-919.	2.2	36
43	Children's Oncology Group's 2013 blueprint for research: Cancer control and supportive care. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1027-1030.	1.5	36
44	Options for the Prevention and Management of Acute Chemotherapy-Induced Nausea and Vomiting in Children. <i>Paediatric Drugs</i> , 2003, 5, 597-613.	3.1	35
45	Pediatric Pharmacotherapeutic Education: Current Status and Recommendations to Fill the Growing Need. <i>Pharmacotherapy</i> , 2005, 25, 1277-1282.	2.6	35
46	Outcome and toxicity of chemotherapy for acute lymphoblastic leukemia in children with down syndrome. <i>Pediatric Blood and Cancer</i> , 2009, 52, 14-19.	1.5	34
47	Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: A retrospective, multi-center review. <i>Pediatric Blood and Cancer</i> , 2015, 62, 496-501.	1.5	34
48	Methylnaltrexone for Opioid-induced Constipation in Pediatric Oncology Patients. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1667-1670.	1.5	33
49	Reducing pain and distress related to needle procedures in children with cancer: A clinical practice guideline. <i>European Journal of Cancer</i> , 2020, 131, 53-67.	2.8	33
50	Ototoxicity following pediatric hematopoietic stem cell transplantation: A prospective cohort study. <i>Pediatric Blood and Cancer</i> , 2004, 42, 598-603.	1.5	32
51	Randomized Controlled Trial of Once- Versus Thrice-Daily Tobramycin in Febrile Neutropenic Children Undergoing Stem Cell Transplantation. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1869-1877.	6.3	31
52	A pilot study of ondansetron plus metopimazine vs. ondansetron monotherapy in children receiving highly emetogenic chemotherapy: a Bayesian randomized serial N-of-1 trials design. <i>Supportive Care in Cancer</i> , 2006, 14, 268-276.	2.2	31
53	Therapeutic Drug Monitoring of Lamotrigine. <i>Annals of Pharmacotherapy</i> , 2002, 36, 917-920.	1.9	29
54	Inferior outcomes for overweight children undergoing allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2007, 140, 071119224223001-???	2.5	29

#	ARTICLE	IF	CITATIONS
55	2016 updated MASCC/ESMO consensus recommendations: Anticipatory nausea and vomiting in children and adults receiving chemotherapy. <i>Supportive Care in Cancer</i> , 2017, 25, 317-321.	2.2	28
56	Validation of the Proxy Version of Symptom Screening in Pediatrics Tool in Children Receiving Cancer Treatments. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 107-112.	1.2	28
57	Optimizing symptom control in children and adolescents with cancer. <i>Pediatric Research</i> , 2019, 86, 573-578.	2.3	27
58	Development of mini-SSPedi for children 4-7 years of age receiving cancer treatments. <i>BMC Cancer</i> , 2019, 19, 32.	2.6	27
59	Optimizing Emetic Control in Children Receiving Antineoplastic Therapy. <i>Paediatric Drugs</i> , 2010, 12, 51-61.	3.1	26
60	Allergic Reactions Associated with Intravenous Versus Intramuscular Pegaspargase: A Retrospective Chart Review. <i>Paediatric Drugs</i> , 2015, 17, 315-321.	3.1	25
61	Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study. <i>Supportive Care in Cancer</i> , 2018, 26, 549-555.	2.2	25
62	Guideline for the Management of <i>Clostridium Difficile</i> Infection in Children and Adolescents With Cancer and Pediatric Hematopoietic Stem-Cell Transplantation Recipients. <i>Journal of Clinical Oncology</i> , 2018, 36, 3162-3171.	1.6	25
63	Comparative Evaluation of Benzylamine Oral Rinse in Children with Antineoplastic-Induced Stomatitis. <i>Drug Intelligence &amp; Clinical Pharmacy</i> , 1987, 21, 359-361.	0.4	23
64	Stability of an extemporaneous oral liquid aprepitant formulation. <i>Supportive Care in Cancer</i> , 2009, 17, 701-706.	2.2	23
65	The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2014, 37, 791-804.	3.2	23
66	Symptom documentation and intervention provision for symptom control in children receiving cancer treatments. <i>European Journal of Cancer</i> , 2019, 109, 120-128.	2.8	23
67	Achievement of Target Cyclosporine Concentrations as a Predictor of Severe Acute Graft Versus Host Disease in Children Undergoing Hematopoietic Stem Cell Transplantation and Receiving Cyclosporine and Methotrexate Prophylaxis. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 750-757.	2.0	22
68	IV Busulfan Dose Individualization in Children undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 576-582.	2.0	22
69	A systematic review and meta-analysis of anti-pseudomonal penicillins and carbapenems in pediatric febrile neutropenia. <i>Supportive Care in Cancer</i> , 2012, 20, 2295-2304.	2.2	21
70	Cyclosporine-Induced Pain Syndrome in a Child Undergoing Hematopoietic Stem Cell Transplant. <i>Annals of Pharmacotherapy</i> , 2009, 43, 767-771.	1.9	20
71	Extent of Agreement in Gentamicin Concentration Between Serum That Is Drawn Peripherally and From Central Venous Catheters. <i>Pediatrics</i> , 2006, 118, e1650-e1656.	2.1	19
72	EFFICACY AND SAFETY OF CASPOFUNGIN FOR THE EMPIRIC MANAGEMENT OF FEVER IN NEUTROPENIC CHILDREN. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 854-856.	2.0	19

#	ARTICLE	IF	CITATIONS
73	A review of symptom screening tools in pediatric cancer patients. <i>Current Opinion in Oncology</i> , 2015, 27, 285-290.	2.4	19
74	Safety and efficacy of nabilone for acute chemotherapy-induced vomiting prophylaxis in pediatric patients: A multicenter, retrospective review. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27374.	1.5	19
75	Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1890-1897.	2.0	19
76	Delayed nausea and vomiting in children receiving antineoplastics. <i>Medical and Pediatric Oncology</i> , 2001, 37, 115-121.	1.0	18
77	Medication Safety: Occurrence and Impact of Unanticipated Variation in Intravenous Methotrexate Dosing. <i>Annals of Pharmacotherapy</i> , 2006, 40, 805-811.	1.9	18
78	Improving paediatric medications: A prescription for Canadian children and youth. <i>Paediatrics and Child Health</i> , 2019, 24, 333-335.	0.6	18
79	Sevelamer hydrochloride: A novel treatment of hyperphosphatemia associated with tumor lysis syndrome in children. <i>Pediatric Blood and Cancer</i> , 2008, 51, 59-61.	1.5	17
80	Initial development of Supportive care Assessment, Prioritization and Recommendations for Kids (SPARK), a symptom screening and management application. <i>BMC Medical Informatics and Decision Making</i> , 2019, 19, 9.	3.0	17
81	Severely bothersome fatigue in children and adolescents with cancer and hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2019, 27, 2665-2671.	2.2	17
82	Veno-occlusive disease after high-dose busulfan+mephalan in neuroblastoma. <i>Bone Marrow Transplantation</i> , 2020, 55, 531-537.	2.4	17
83	Fluoroquinolones in Children With Fever and Neutropenia. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 431-435.	2.0	16
84	Chemotherapy-Induced Nausea and Vomiting Prophylaxis: Practice Within the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2016, 63, 887-892.	1.5	16
85	Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27584.	1.5	16
86	A Meta-analysis of Antipseudomonal Penicillins and Cephalosporins in Pediatric Patients With Fever and Neutropenia. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 353-359.	2.0	15
87	Acupressure bands do not improve chemotherapy-induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single-blind, randomized controlled trial. <i>Cancer</i> , 2018, 124, 1188-1196.	4.1	15
88	Discordance between pediatric self-report and parent proxy-report symptom scores and creation of a dyad symptom screening tool (co-SSPedi). <i>Cancer Medicine</i> , 2020, 9, 5526-5534.	2.8	15
89	Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults. <i>Supportive Care in Cancer</i> , 2020, 28, 4761-4769.	2.2	15
90	Determination of a Limited Sampling Strategy for IV Busulfan Dose Individualization in Children. <i>Blood</i> , 2006, 108, 2942-2942.	1.4	15

#	ARTICLE	IF	CITATIONS
91	Outcomes of antiemetic prophylaxis in children undergoing bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 119-124.	2.4	14
92	Poor chemotherapy-induced nausea and vomiting control in children receiving intermediate or high dose methotrexate. <i>Supportive Care in Cancer</i> , 2016, 24, 1365-1371.	2.2	14
93	Changes in taste among pediatric patients with cancer and hematopoietic stem cell transplantation recipients. <i>Quality of Life Research</i> , 2019, 28, 2941-2949.	3.1	14
94	Reducing pain in children with cancer: Methodology for the development of a clinical practice guideline. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27698.	1.5	14
95	Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1424-1431.	2.0	14
96	Recommendations for Age-Appropriate Testing, Timing, and Frequency of Audiologic Monitoring During Childhood Cancer Treatment. <i>JAMA Oncology</i> , 2021, 7, 1550.	7.1	14
97	Once-Daily Gentamicin Dosing in Children with Febrile Neutropenia Resulting from Antineoplastic Therapy. <i>Pharmacotherapy</i> , 2010, 30, 43-51.	2.6	13
98	Prediction of Area under the Cyclosporine Concentration Versus Time Curve in Children Undergoing Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 418-423.	2.0	13
99	The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis. <i>Drug Safety</i> , 2016, 39, 509-516.	3.2	13
100	Longitudinal evaluation of Supportive care Prioritization, Assessment and Recommendations for Kids (SPARK), a symptom screening and management application. <i>BMC Cancer</i> , 2019, 19, 458.	2.6	13
101	Identifying clinical practice guidelines for the supportive care of children with cancer: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27471.	1.5	13
102	Prevention and treatment of anticipatory chemotherapy-induced nausea and vomiting in pediatric cancer patients and hematopoietic stem cell recipients: Clinical practice guideline update. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28947.	1.5	13
103	Factors Associated With Chemotherapy-Induced Vomiting Control in Pediatric Patients Receiving Moderately or Highly Emetogenic Chemotherapy: A Pooled Analysis. <i>Journal of Clinical Oncology</i> , 2020, 38, 2499-2509.	1.6	12
104	Determination of Area Under the Whole Blood Concentration versus Time Curve after First Intravenous Cyclosporine Dose in Children Undergoing Hematopoietic Stem Cell Transplant: Limited Sampling Strategies. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 434-438.	2.0	12
105	Tobramycin Pharmacokinetics in Children with Febrile Neutropenia Undergoing Stem Cell Transplantation: Once-Daily versus Thrice-Daily Administration. <i>Pharmacotherapy</i> , 2004, 24, 564-573.	2.6	11
106	Nausea and vomiting in children and adolescents receiving intrathecal methotrexate: A prospective, observational study. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26603.	1.5	11
107	Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 97-110.	2.4	11
108	Taste changes in children with cancer and hematopoietic stem cell transplant recipients. <i>Supportive Care in Cancer</i> , 2019, 27, 2247-2254.	2.2	10

#	ARTICLE	IF	CITATIONS
109	Reasons for disagreement between proxy-report and self-report rating of symptoms in children receiving cancer therapies. <i>Supportive Care in Cancer</i> , 2021, 29, 4165-4170.	2.2	10
110	Disposition of Two Oral Formulations of Cyclosporine in Pediatric Patients Receiving Hematopoietic Stem Cell Transplants. <i>Pharmacotherapy</i> , 2006, 26, 15-22.	2.6	8
111	Parent Attributions About Child Symptoms Related to Cancer Therapy. <i>Journal of Pediatric Oncology Nursing</i> , 2017, 34, 44-50.	1.5	8
112	Dexamethasone dosing for prevention of acute chemotherapy-induced vomiting in pediatric patients: A systematic review. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28716.	1.5	8
113	Identifying clinical practice guidelines for symptom control in pediatric oncology. <i>Supportive Care in Cancer</i> , 2021, 29, 7049-7055.	2.2	8
114	Perceptions of parents of pediatric patients with acute lymphoblastic leukemia on oral chemotherapy administration: A qualitative analysis. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29329.	1.5	8
115	Safety of Dexamethasone for Nausea and Vomiting Prophylaxis in Children Receiving Hematopoietic Stem Cell Transplantation. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, e278-e282.	0.6	7
116	Feasibility of a randomized controlled trial of symptom screening and feedback to healthcare providers compared with standard of care using the SPARK platform. <i>Supportive Care in Cancer</i> , 2020, 28, 2729-2734.	2.2	7
117	Lexicon for guidance terminology in pediatric hematology/oncology: A White Paper. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28170.	1.5	7
118	Facilitators and barriers to clinical practice guideline-consistent supportive care at pediatric oncology institutions: a Children's Oncology Group study. <i>Implementation Science Communications</i> , 2021, 2, 106.	2.2	7
119	Quality Control of Busulfan Plasma Quantitation, Modeling, and Dosing: An Interlaboratory Proficiency Testing Program. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 657-663.	2.0	7
120	<i>Clostridioides difficile</i> infection in paediatric patients with cancer and haematopoietic stem cell transplant recipients. <i>European Journal of Cancer</i> , 2022, 171, 1-9.	2.8	7
121	Documentation of Pediatric Drug Safety in Manufacturers' Product Monographs. <i>Paediatric Drugs</i> , 2008, 10, 193-197.	3.1	6
122	Daclizumab therapy for children with corticosteroid-resistant acute graft-versus-host disease. <i>Pediatric Transplantation</i> , 2009, 13, 332-337.	1.0	6
123	Barriers to symptom management care pathway implementation in pediatric Cancer. <i>BMC Health Services Research</i> , 2021, 21, 1068.	2.2	6
124	A Reliable and Safe Method of Collecting Blood Samples from Implantable Central Venous Catheters for Determination of Plasma Gentamicin Concentrations. <i>Pharmacotherapy</i> , 2011, 31, 776-784.	2.6	5
125	Chemotherapy-induced nausea and vomiting control in pediatric patients receiving ifosfamide plus etoposide: a prospective, observational study. <i>Supportive Care in Cancer</i> , 2020, 28, 933-938.	2.2	5
126	Finalising the administration of co-SSPedi, a dyad approach to symptom screening for paediatric patients receiving cancer treatments. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e469-e475.	1.6	5



#	ARTICLE	IF	CITATIONS
127	Reliability and validity of proxy-SSPedi and mini-SSPedi in pediatric patients 2-7 years receiving cancer treatments. <i>BMC Cancer</i> , 2022, 22, .	2.6	5
128	Pharmacist intervention in prescribing of cefuroxime for pediatric patients. <i>American Journal of Health-System Pharmacy</i> , 1990, 47, 1350-1353.	1.0	4
129	Stability of propafenone hydrochloride in i.v. solutions. <i>American Journal of Health-System Pharmacy</i> , 1997, 54, 1293-1295.	1.0	4
130	Determination of initial i.v. CYA dosage to achieve target AUC values in pediatric hematopoietic stem cell transplant patients. <i>Bone Marrow Transplantation</i> , 2008, 42, 455-459.	2.4	4
131	Relationship between cyclosporine area-under-the curve and acute graft versus host disease in pediatric patients undergoing hematopoietic stem cell transplant: A prospective, multicenter study. <i>Pediatric Hematology and Oncology</i> , 2018, 35, 288-296.	0.8	4
132	Creating and adapting an infection management care pathway in pediatric oncology. <i>Supportive Care in Cancer</i> , 0, , .	2.2	4
133	Oral syringe for extemporaneously preparing doses. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 735-735.	1.0	3
134	Comparative effectiveness research in antineoplastic-induced nausea and vomiting control in children. <i>Journal of Comparative Effectiveness Research</i> , 2014, 3, 185-196.	1.4	3
135	Strategies facilitating practice change in pediatric cancer: a systematic review. <i>International Journal for Quality in Health Care</i> , 2016, 28, 426-432.	1.8	3
136	Relative bioavailability of an extemporaneously prepared aprepitant oral suspension in healthy adults. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1907-1915.	0.9	3
137	Chemotherapy-induced nausea and vomiting from oral chemotherapy for childhood acute lymphoblastic leukaemia: feasibility study. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, e646-e649.	1.6	3
138	Clinical decisions following implementation of asparaginase activity monitoring in pediatric patients with acute lymphoblastic leukemia: Experience from a single-center study. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28044.	1.5	3
139	Changes in hunger among pediatric patients with cancer and hematopoietic stem cell transplantation recipients. <i>Supportive Care in Cancer</i> , 2020, 28, 5795-5801.	2.2	3
140	Feeling scared or worried self-report in children receiving cancer treatments using the Symptom Screening in Pediatrics Tool (SSPedi). <i>Supportive Care in Cancer</i> , 2021, 29, 3137-3144.	2.2	3
141	Symptom Screening in Pediatrics Tool in children and adolescents with high-risk malignancies: a pilot study. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e70-e73.	1.6	3
142	Describing taste changes and their potential impacts on paediatric patients receiving cancer treatments. <i>BMJ Supportive and Palliative Care</i> , 2023, 13, e382-e388.	1.6	3
143	Dismal response to high-dose methylprednisolone after failure to respond to standard dose in patients with acute GVHD. <i>Bone Marrow Transplantation</i> , 2010, 45, 1749-1753.	2.4	2
144	Effect of acute graft-versus-host disease on the outcome of second allogeneic hematopoietic stem cell transplant in children. <i>Leukemia and Lymphoma</i> , 2013, 54, 105-109.	1.3	2

#	ARTICLE	IF	CITATIONS
145	Methodological issues identified during cognitive interviews in the development of a pediatric cancer symptom screening tool. <i>Psycho-Oncology</i> , 2016, 25, 349-353.	2.3	2
146	Chemotherapy-induced vomiting in children: some progress, more questions. <i>Lancet Oncology</i> , The, 2016, 17, 264-265.	10.7	2
147	Comment on: Olanzapine for chemotherapy-induced nausea: Lessons learned from child and adolescent psychiatry. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27456.	1.5	2
148	Development of the SPARK family member web pages to improve symptom management for pediatric patients receiving cancer treatments. <i>BMC Cancer</i> , 2020, 20, 923.	2.6	2
149	Stability of extemporaneously compounded temozolomide 10 mg/mL suspensions in Oral Mix SF <sup>®</sup> in glass and plastic bottles and plastic syringes. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 78-87.	0.9	2
150	Translation of the Pediatric Nausea Assessment Tool (PeNAT) Into Spanish and Evaluating Understandability Among Spanish-Speaking Hispanic American Children and Adolescents Receiving Chemotherapy. <i>Hispanic Health Care International</i> , 2022, 20, 33-39.	0.9	2
151	Appropriate busulfan dosing. <i>Bone Marrow Transplantation</i> , 2005, 35, 199-200.	2.4	1
152	Cyclosporine Dose Intensity and Risk of Acute Graft-versus-Host Disease: Trough versus Area under the Curve. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 866-867.	2.0	1
153	Response to "Aprepitant and fosaprepitant decrease the effectiveness of hormonal contraceptives". <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 604-604.	2.4	1
154	Measurement properties of instruments to assess pain in children and adolescents with cancer: a systematic review protocol. <i>Systematic Reviews</i> , 2019, 8, 33.	5.3	1
155	Conventional compared to network meta-analysis to evaluate antibiotic prophylaxis in patients with cancer and haematopoietic stem cell transplantation recipients. <i>BMJ Evidence-Based Medicine</i> , 2020, 26, bmjebm-2020-111362.	3.5	1
156	Adherence to clinical practice guidelines for the prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults with cancer receiving their first cycle of highly emetogenic chemotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 19-19.	1.6	1
157	Reply to "Pharmacokinetic and Analytical Issues in Busulfan Area Under the Curve Estimation and Simulation". <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 186.	2.0	0
158	L'optimisation des médicaments à usage pédiatrique : une prescription pour les enfants et les adolescents canadiens. <i>Paediatrics and Child Health</i> , 2019, 24, 336-339.	0.6	0
159	Response to Kawedia et al Letter to Editor in Response to the Article by McCune Et Al "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e235-e236.	2.0	0
160	Functional GSTA1 Haplotypes Affect Clearance and Toxicity of Busulfan When Administered in 16 Doses to Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation: A Multicenter Prospective Study on Behalf of the Pediatric Disease Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2016, 128, 665-665.	1.4	0